Abstract
Introduction
Chronic heart failure (CHF) is a known and significant risk factor for acute pulmonary embolism (APE). Moreover, patients with APE and coexisting CHF are characterized by a higher mortality rate than APE patients without CHF [1] . In large PE registries, such as ICOPER registry, CHF was observed in 10.5% of patients with APE and was found to be an independent mortality risk factor with a hazard ratio (HR) of 2.4 [2] . Similar symptomatology of both diseases still hinders diagnosis of APE and the implementation of an appropriate treatment. In patients with advanced CHF, prevalence of APE increases and significantly influences the length of hospitalization, frequency of re-hospitalization or frequency of early death [3, 4] . In the available literature, there are few reports evaluating the influence of APE on the survival of patients with CHF.
The aim of this study was a diagnostic evaluation of the influence of past APE on the early and delayed survival of patients with CHF.
Methods

Patient population
A prospective study included 87 consecutive patients with CHF admitted to hospital due to sudden resting dyspnoea. The suspicion of APE was determined additionally based on the intermediate clinical probability according to the Wells scale, positive result of D-dimer > 0.5 µg/mL assay measured with immunoturbobidimetric method LIATEST, and a maximal velocity of tricuspid valve regurgitation (TR) > 2.8 m/s. Etiology of CHF in both studied groups is shown in Table 1 .
This study was approved by the Regional Bioethics Committee, and all patients provided informed consent.
Patients were divided into two groups according to the results of spiral computed tomography (sCT) of the thorax and compression ultrasound (CUS) of lower extremities veins. Pulmonary embolism was diagnosed when at least segmental thromboemboli were visualized. Six-and 36-month total mortality and cardiovascular (CV) mortality were evaluated. Analyzis of CV mortality included: myocardial infarction, sudden cardiac death, APE, decompensated CHF and cerebral stroke; whereas the analysis of total mortality comprised the remaining causes including the neoplastic disease. Data on patients deaths were obtained from the regional Department of National Health Fund. Also, potential and independent risk factors for the death of patients with CHF under short-and long-term observations were determined.
Definitions
CHF was diagnozed based on a clinical findings according to Framingham criteria and earlier medical records. APE was recognized when at least one filling defect at sCT was visualized in at least segmental arteries. APE was excluded in the case of a negative sCT result and a negative CUS result. CUS was carried out in 4 points within femoral and popliteal veins. The total collapse of a vessel wall excluded the presence of thrombosis; whereas, a lack of total collapse of the vessel confirmed the presence of proximal thrombosis [5, 6] . Renal failure was diagnozed when serum creatinine level was found to be ≥ 1.3 mg/dL on admission. Hyponatremia was diagnozed when sodium (Na) level in blood serum was < 136 mmol/L on admission.
Patients with acute coronary syndromes within the last 14 days and patients without diagnozed CHF were not included in this study.
Echocardiographic examination
For all patients, a standard echocardiographic examination was performed with a 2.5 MHz trans- Table 1 . Etiology of chronic heart failure (CHF) in both studied groups.
Causes of CHF (%)
All patients (n = 87) PE+ (n = 35) PE-(n = 52) P [7, 8] . With the use of one-dimensional M-mode examination, a tricuspid annular plane systolic excursion (TAPSE) was measured [9] .
Treatment
Patients with CHF received standard therapy for heart failure: angiotensin converting enzyme (ACE)-inhibitor or AT1 receptor antagonist, beta--receptors antagonist, diuretics or spironolactone. In some patients with persistent atrial fibrillation digoxin was used. Patients with confirmed APE were treated with intravenous infusion of non-fractionated heparin in a therapeutic dose under the control of activated partial thromboplastin time 50-70 s for at least 5 days; and in all patients oral anticoagulant was included in their treatment under the control of normalized prothrombin time (INR) of 2.0-3.0 value. Non-fractionated heparin was discontinued after 2 days INR > 2. All patients with confirmed APE were discharged from hospital on anticoagulant treatment recommended for at least 3 months.
Statistical analysis
For comparison, Student's t test or Mann-Whitney test were used depending on the distribution of variables. Data on normal distribution were presented as a mean with standard deviation (SD). Variables not meeting the requirements of a normal distribution were presented as a median with a range of values; the c 2 test was used for comparison of variables in multi-partition tables. To identify predictors of mortality, Cox proportional hazards regression analysis was performed. Continuous variables were analyzed in the analysis of dichotomous form according to significant cut-off points. For multivariate analysis, only those parameters were included which demonstrated statistical significance (p < 0.05) in univariate analysis. Survival time of patients was determined by the Kaplan-Meier curve; the log-rank test was used for comparison. Statistical analyzis was carried out with the use of Statistica 6 software.
Results
The study comprized 87 consecutive patients with CHF admitted to hospital due to episode of sudden dyspnoea at rest, with clinically suspected APE of at least a moderate clinical probability according to the Wells' probability scale [10] , positive result of D-dimer > 0.5 µg/mL and TR > 2.8 m/s. Eventually, APE was tomographically diagnosed in 35 patients, while in the remaining 52 subjects APE was excluded. Demographic and clinical characteristics of patients in both groups are presented in Table 2 .
The mean age of the patients in both groups, with confirmed APE and without APE, was similar. Incidence of concomitant diseases, such as: arterial hypertension, history of myocardial infarction, atrial fibrillation, chronic obstructive pulmonary disease was also similar for both groups.
CHF of NYHA class IV, III and II ware present in a similar percentage in both studied groups. However, at echocardiographic examination, patients with confirmed APE were characterized by lower LVDD, higher RVDD, decreased RV contractility assessed with TAPSE than patients with excluded APE. However, patients in both groups did not differ in TRPG value and LVEF. Plasma creatinine level was significantly higher in the APE group, although renal failure was present with a similar frequency in both groups, 43.3% of APE patients and in 31.2% of patients without APE, respectively (p = 0.27). Venous thromboembolism (VTE) risk factors, the presence of the neoplastic disease, a history of surgery within the past month and a positive history of APE or venous thrombosis in both examined groups were similar. Treatment of CHF in both groups did not differ significantly with regard to the frequency of beta-receptors antagonists use, ACE inhibitors, AT1 receptors antagonists, diuretics, spironolactone and cardiac glycosides and is shown in Table 3 . Obviously patients with diagnozed APE were anticoagulated and at discharge 85% of them were treated with oral anticoagulants according to INR, and remaining 15% were treated with weight adjusted dose of low molecular weight heparin. Patients without APE received an oral anticoagulant at discharge in 53% of cases. The presence of atrial fibrillation was the main indication for long term anticoagulant prophylaxis in these patients.
During a 6-month observation period, total mortality was found to be higher in a group of patients with confirmed APE when compared to patients without APE and was 34.4% vs. 13.4%, respectively (p = 0.02). However, at 36-month follow-up, total mortality did not differ statistically between both groups, but the tendency for a higher mortality rate was observed in patients with APE, which was 51.4% vs. 36.5%, respectively (p = 0.11) (Fig. 1) . Interestingly, in a 6-month observation, CV mortality was higher in patients with APE than in the group without APE and was 28.5% vs. 11.5%, respectively (p = 0.02); whereas in Table 4 ). In order to assess independent risk factors for the total mortality of patients with CHF, univariate and multivariate analyses of Cox proportional hazards regression analysis were performed. Potential significance of clinical, echocardiographic and laboratory parameters was analyzed. In a 6-month observation period, mortality predictors of included: presence of APE: HR = 3.2 (95% CI 1.3-12.2), p = 0.02, hyponatremia (NaCl < 136 mmol/L): HR = 2,8 (95% CI 1.3-18.5), p = 0.03 and renal failure (serum creatinine ≥ 1.3 mg/dL): HR = 2.6 (95% CI 1.2-17.4), p = 0.04 (Table 5) .
However, in a multivariate analysis, the only independent risk factor for death in a 6-month observation period was the presence of APE with HR = 2.7 (95% CI 1.1-24.4), p = 0.04, while hyponatremia and renal failure were not independent mortality predictors (Table 6 ). In a long-term 36-month follow-up period, not found the potential risk factor for death of patients with CHF.
Discussion
Decompensated chronic heart failure is a frequent cause of CV hospitalization [11] [12] [13] [14] [15] .
Recent registries demonstrated significant inhospital mortality of CHF patients of 4-7% [16, 17] . It is generally accepted that patients with CHF are characterized by an increased risk of VTE. In various studies, the incidence of APE or deep vein thrombosis in the population of patients hospitalized due to CHF ranged from 4% to 14% [18] [19] [20] . In another study, the incidence of APE in a group of patients with CHF was 9.1% despite adequate use Table 6 . Multivariate predictors of death of patients with chronic heart failure at 6 months. Table 4 . Total and cardiovascular mortality of patients of both groups.
Variables
All patients (n = 87) PE+ (n = 35) PE-(n = 52) P of antithrombotic prophylaxis in 2/3 of patients [3] . In the ICOPER registry with 2554 patients, APE accompanying CHF was diagnosed in 10.5% of patients [2] . The presence of CHF in patients with APE worsens their prognosis and is an independent risk factor for death [1, 2] . Darze et al. [4] observed that APE worsens the prognosis or increases the frequency of hospitalization in a 3-month observation in patients with CHF. In our study, we compared patients with CHF and concomitant APE with patients with CHF and excluded APE in short-and long-term observations. In a 6-month observation, the total and CV mortality of patients with APE was significantly higher compared to patients without APE: 34.4% vs. 13.4% (p = 0.02) and 28.5% vs. 11.5% (p = 0.02), respectively. However, the 36-month total and CV mortality for both studied groups was similar. It partly confirms the results of the Darze et al. study [4] , which showed a trend towards a higher 3-month mortality rate for patients with CHF with confirmed APE compared to patients with CHF. In that study, a combination of 3-month mortality with 3-month re-hospitalization showed a significant predominance of adverse events in patients with APE by 72.2% vs. 43.5%, respectively (p = 0.02) [4] . In our study, total and CV mortality was evaluated and demonstrated a significant difference in frequency against patients with confirmed APE in a 6-month observation. To our knowledge, this is the first study which compares patients with CHF with confirmed APE during hospitalization with patients with CHF and excluded APE. In the Darze et al. study [4] , a group of 18 patients with confirmed APE was compared with a group of 180 patients of whom only in 18 cases APE was excluded based on a negative result of sCT or pulmonary scyntygraphy. In that study, an independent factor for death or 3-month re-hospitalization was a history of APE (OR = 4.0, 95% CI 1.1-15.1, p = 0.038). That study confirms our results that an independent risk factor for death of patients with CHF is a history of APE in a 6-month observation (HR = 2.7, 95% CI 1.1-24.4, p = 0.04).
Persistent higher mortality of patients with CHF and APE during a 6-month period following discharge from hospital compared to patients without APE may be explained by its adverse influence on the clinical course of patients with CHF. A sudden increase of pulmonary pressure observed during APE results in pressure and volume overload of the RV. In previous studies, it was reported that prognosis for patients after APE depends mostly on RV efficiency and recurrences of APE. In our study, all patients with APE were at a low risk of early death and received prophylactic treatment with an oral anticoagulant in 85% of cases or low molecular weight heparin in 15% of cases. Despite an appropriate anticoagulant therapy, patients with a history of APE were characterized by a higher total and CV mortality rate than patients without APE in a 6-month observation period following discharge from hospital. Similar risk factors for VTE and acute coronary syndrome have been discussed recently. Can similar mechanisms of venous and arterial thrombosis cause an increase in the frequency of APE events and an increase in thromboembolic complications frequency after APE? Such a thesis is quite bold at present.
If the results of our study, indicating that APE is an independent factor for poor prognosis of patients with CHF, are confirmed in further analyzes, we should consider a simple and efficient model of APE diagnosis in patients with CHF and a more efficient secondary anticoagulant prophylaxis following discharge from hospital.
Limitations of the study
The main limitation of our study is the fact that this one-center observation which was carried out with a relatively small group of patients.
Conclusions
Patients with CHF and acute episode of pulmonary embolism are characterized by a higher 6-month total and CV mortality rate following discharge from hospital compared to patients hospitalized due to acute CHF decompensation. Moreover, recent episode of PE in patients with CHF is an independent risk factor for early mortality in a 6-month follow-up; whereas in a 36-month observation, past APE had no influence on mortality.
